1-phenoxy-2-pentanol | 87034-17-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-phenoxy-2-pentanol
• 英文别名: 1-Phenoxypentan-2-ol
• CAS: 87034-17-1
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.247
• InChiKey: NNZSIEVRBBZXBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-phenoxy-2-pentanol 在 吡啶 、 二溴亚砜 作用下， 以 氯仿 为溶剂， 生成 2-Brom-1-phenoxy-pentan
  参考文献：
  名称：

  单胺氧化酶抑制剂。一系列取代的烷基肼的合成与评估。

  摘要：

  DOI：

  10.1021/jm00337a015
• 作为产物：
  描述：

  1-苯氧基-2-戊酮 在 甲醇 、 sodium tetrahydroborate 作用下， 反应 2.0h， 以91%的产率得到1-phenoxy-2-pentanol
  参考文献：
  名称：

  砜基团是酮的不对称转移加氢的通用和可移动的导向基团。

  摘要：

  砜官能团具有通过采用一位置远离η直接酮的不对称转移氢化（ATH）在[（芳烃）的Ru（TsDPEN）H]复合物的存在强烈的容量6 -arene环。这种偏好为预测不对称还原感提供了一种手段。砜基团也促进了一系列还原底物的形成，并且其容易地去除提供了对映体富集的醇的途径，否则，通过相应的酮的直接ATH很难制备对映体富集的醇。

  DOI：

  10.1002/anie.202004658

文献信息

• Fused Heterocyclic Compounds as Ion Channel Modulators
  申请人：Kobayashi Tetsuya

  公开号：US20120010192A1

  公开（公告）日：2012-01-12

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类是钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该类化合物的结构由式I给出：其中R1、R2、R3、R4和R5如本文所述，以及制备和使用该类化合物的方法，以及含有这些化合物的药物组合物。
• Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same
  申请人：Fan Chin-Tsai

  公开号：US20090318488A1

  公开（公告）日：2009-12-24

  The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases.

  本发明揭示了阿波啶化合物和含羧基的试剂的新型药用可接受盐。此外，本发明还揭示了制备药用可接受盐的方法。这些药用可接受盐适用于治疗和/或预防高血糖病和/或几种与氧化应激相关的疾病。
• Water content influences the selectivity of CALB-catalyzed kinetic resolution of phenoxymethyl-substituted secondary alcohols
  作者：Elisabeth Egholm Jacobsen、Thorleif Anthonsen

  DOI：10.1139/v02-068

  日期：2002.6.1

  Derivatives of 1-phenoxy-2-alkanols were kinetically resolved by esterification with irreversible and reversible acyl donors using lipase B from Candida antarctica (Novozyme 435) as a catalyst. To optimize the relative rate of reaction (the E-value), esterifications in eight different solvents with different water activities were performed. For 3-bromo-1-phenoxy-2-propanol (1), the E-values in all the solvents were higher when the water activity was increased, while the E-values for 1-phenoxy-2-pentanol (2) and 3-chloro-1-phenoxy-2-propanol (3) decreased by increasing water activity. The water content of the various reaction media with the same water activity was determined. Solvents such as 1,4-dioxane, acetonitrile, and tetrahydrofuran contained much more water than hexane, carbon tetrachloride, cyclohexane, toluene, and benzene. At high-water activity, the high-water content of the former group of solvents resulted in termination of the reaction at low conversion. The reason seemed to be that the acyl donor and possibly also the produced esters were hydrolyzed. This was not the case when the esterification was performed in water-immiscible solvents with the same water activity.Key words: kinetic resolution, E-value, solvents, water activity, water content.

  1-苯氧基-2-烷醇的衍生物通过使用来自南极酵母(Candida antarctica，Novozyme 435)的脂肪酶B作为催化剂，通过与不可逆和可逆酰基供体酯化来进行动力学分辨。为了优化反应的相对速率（E值），在具有不同水活性的八种不同溶剂中进行了酯化反应。对于3-溴-1-苯氧基-2-丙醇（1），当水活性增加时，所有溶剂中的E值都更高，而对于1-苯氧基-2-戊醇（2）和3-氯-1-苯氧基-2-丙醇（3），随着水活性的增加，E值降低。确定了具有相同水活性的各种反应介质的含水量。1,4-二噁烷、乙腈和四氢呋喃等溶剂含水量比己烷、四氯化碳、环己烷、甲苯和苯更多。在高水活性下，前一组溶剂的高含水量导致在低转化率时终止反应。原因似乎是酰基供体，可能也是产生的酯被水解。当在具有相同水活性的不相溶水溶剂中进行酯化反应时，情况并非如此。关键词：动力学分辨，E值，溶剂，水活性，含水量。
• Enhanced selectivity in Novozym 435 catalyzed kinetic resolution of secondary alcohols and butanoates caused by the (R)-alcohols
  作者：Elisabeth Egholm Jacobsen、Erik van Hellemond、Anders Riise Moen、Lucia Camino Vazquez Prado、Thorleif Anthonsen

  DOI：10.1016/j.tetlet.2003.09.105

  日期：2003.11.10

  In esterifications of secondary alcohols catalyzed by immobilized lipase B from Candida antarctica (Novozym 435) the E-values decreased during the reaction. Hydrolysis of the corresponding butanoates showed the opposite effect. When an enantiopure (R)-alcohol, related but different, was added to the transesterification reaction, the E-value was significantly enhanced.

  在固定化来自南极假丝酵母的脂肪酶B （Novozym 435）催化的仲醇的酯化反应中，E值降低。相应的丁酸酯的水解显示相反的作用。当将相关但不同的对映体（R）-醇加入酯交换反应中时，E-值显着提高。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150080370A1

  公开（公告）日：2015-03-19

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是钠通道抑制剂，用于治疗各种疾病状态，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由公式I给出：其中R1，R2，R3，R4和R5如本文所述，涉及该化合物的制备和使用方法以及包含该化合物的制药组合物。